Biogen prepares to fight Medicare over Alzheimer’s drug limits


14 January 2022 - Draft rule limits access to hundreds of patients, CEO says.

Biogen executives vowed to fight hard to reverse Medicare’s preliminary decision that would sharply limit coverage of the company’s Alzheimer’s drug, while saying more cost cuts and strategic measures are possible if the decision stands.

Read Bloomberg article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Market access